Flu season is knocking on our doors and timing could not have en better for the newest pharmaceutical penny stock to commence trading. Late Tuesday afternoon, shares of Vansen Pharma, Inc. (VNSN) traded for the first time since their name and ticker change from Okana Ventures, Inc. (OKNV) and subsequent 12-for-1 stock split. Having made some multi-million dollar acquisitions in recent months for the product rights of a couple of very popular acute bacterial exacerbation drugs, taking notice to the early stages of VNSN stock trading could be the preventative cure to missing out on some short-term gains.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
VNSN Stock Quote
Market Cap: 43.25M
Last: 0.51 ▼ -0.34 (-40.00%)
Volume: 5,500
Open: 0.85
High: 0.85
Low: 0.51
Authorized: 1,200,000,000
Issued and Outstanding: 84,800,004
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
Back o July 30, 2013, Okana Ventures closed an asset purchase agreement with Vansen Pharma, Inc., acquiring the right, title and interest to certain Spectracef® and cefditoren pivoxil products in the United States, along with related contracts, records, inventories and product registrations. They don’t get the right, title or interest to the products in Canada, but healthcare is free north of the border so who really cares.
The $900,000 plus 43,500,000 shares of VNSN stock was the first move Richard Azani, President, CEO, CFO, Treasurer, Secretary and Director, and Patrick Charles Frankham, Director, made.
On August 30, they announced the acquisition for the North American product rights for FACTIVE® (Gemifloxacin Mesylate) tablets from Merus Labs International (NASDAQ:MSLI). This $3.4 million acquisition for the license to the FACTIVE® trademark and patent, inventory on hand, various contingent liabilities, and certain related intellectual property and other information and materials required to market the FDA-approved quinolone with 5-day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.
Not being too sure where the $2.2 million paid on closing came from since there was only $176 in cash as of June 30, 2013, Vansen Pharma raised some $1,450,000 through a private investor by issuing 3,152,174 shares of VNSN stock at $0.46 per share. Seeing as how $800,000 is scheduled to be paid quarterly installments over the next 15 months, as well as 3,000,000 shares of VNSN to be distributed, in order to complete the FACTIVE® deal, sales should begin flowing relatively quickly and VNSN stock should see some consistent activity begin to build up as we enter into Winter.
About VNSN Stock
Vansen Pharma, Inc. is a development stag company focused on specialty pharmaceutical products like Spectracef® and its authorized generic, cefditoren pivoxil, to major wholesalers and pharmacy chains.
Click here to view the SEC filings for VNSN.
Click here to view the website for Vansen Pharma.
Bottom Line:
Fresh, clean, and throwing tons of money around for rights to sell drugs, VNSN stock is one penny stock you will want to be watching for the remainder of the week. The likelihood of seeing volume exceed 1,000,000 is highly unlikely this week, but once this one kicks off, having the inside track to VNSN could help you avoid grabbing for the tissues.
Stay Connected With Us:
Our Next Pick Is Coming Soon!
Text Keyword “AIMHIGH” To 99000 To Make Sure You Don’t Miss It!
OCT
